vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $19.1M, roughly 1.8× NewAmsterdam Pharma Co N.V.). Clearfield, Inc. runs the higher net margin — -1.8% vs -90.7%, a 88.9% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -3.2%). Clearfield, Inc. produced more free cash flow last quarter ($-2.4M vs $-37.8M).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
CLFD vs NAMS — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $19.1M |
| Net Profit | $-614.0K | $-17.4M |
| Gross Margin | 33.2% | — |
| Operating Margin | -5.3% | -186.1% |
| Net Margin | -1.8% | -90.7% |
| Revenue YoY | -3.2% | 740.1% |
| Net Profit YoY | 67.8% | 55.5% |
| EPS (diluted) | $-0.04 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | — | ||
| Q3 25 | $23.4M | — | ||
| Q2 25 | $49.9M | $19.1M | ||
| Q1 25 | $47.2M | — | ||
| Q4 24 | $29.7M | $12.8M | ||
| Q3 24 | $5.6M | $29.1M | ||
| Q2 24 | $48.8M | — | ||
| Q1 24 | $36.9M | — |
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $-9.1M | — | ||
| Q2 25 | $1.6M | $-17.4M | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $-1.9M | $-92.2M | ||
| Q3 24 | — | $-16.6M | ||
| Q2 24 | $-447.0K | — | ||
| Q1 24 | $-5.9M | — |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | — | ||
| Q3 25 | 10.3% | — | ||
| Q2 25 | 3.0% | -186.1% | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | -6.9% | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | -26.4% | — |
| Q4 25 | -1.8% | — | ||
| Q3 25 | -38.8% | — | ||
| Q2 25 | 3.2% | -90.7% | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | -6.4% | -721.7% | ||
| Q3 24 | — | -57.2% | ||
| Q2 24 | -0.9% | — | ||
| Q1 24 | -16.0% | — |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.65 | — | ||
| Q2 25 | $0.11 | $-0.15 | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $-0.13 | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $249.7M | $778.5M |
| Total Assets | $268.1M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | — | ||
| Q3 25 | $106.0M | — | ||
| Q2 25 | $117.2M | $739.2M | ||
| Q1 25 | $112.0M | — | ||
| Q4 24 | $113.0M | $834.2M | ||
| Q3 24 | $129.0M | $422.7M | ||
| Q2 24 | $123.8M | — | ||
| Q1 24 | $142.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $249.7M | — | ||
| Q3 25 | $256.2M | — | ||
| Q2 25 | $264.5M | $778.5M | ||
| Q1 25 | $265.9M | — | ||
| Q4 24 | $267.4M | $757.5M | ||
| Q3 24 | $275.8M | $378.9M | ||
| Q2 24 | $274.6M | — | ||
| Q1 24 | $279.2M | — |
| Q4 25 | $268.1M | — | ||
| Q3 25 | $306.2M | — | ||
| Q2 25 | $314.7M | $815.1M | ||
| Q1 25 | $310.9M | — | ||
| Q4 24 | $303.2M | $864.6M | ||
| Q3 24 | $315.3M | $439.2M | ||
| Q2 24 | $318.1M | — | ||
| Q1 24 | $315.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $-37.7M |
| Free Cash FlowOCF − Capex | $-2.4M | $-37.8M |
| FCF MarginFCF / Revenue | -7.1% | -197.2% |
| Capex IntensityCapex / Revenue | 2.9% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.9M | $-37.7M | ||
| Q1 25 | $3.0M | — | ||
| Q4 24 | $7.2M | $-37.5M | ||
| Q3 24 | $22.2M | $-12.5M | ||
| Q2 24 | $4.0M | — | ||
| Q1 24 | $-5.7M | — |
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | $-37.8M | ||
| Q1 25 | $654.0K | — | ||
| Q4 24 | $5.1M | $-37.5M | ||
| Q3 24 | $18.2M | $-12.6M | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $-7.7M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | -197.2% | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 17.1% | -293.5% | ||
| Q3 24 | 323.0% | -43.2% | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -20.8% | — |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 0.8% | 0.5% | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 7.0% | 0.0% | ||
| Q3 24 | 71.4% | 0.3% | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 5.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
